Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer Based on 11 Gene Tests of Homologous Recombination Pathway

NCT04337632 Phase 3 UNKNOWN

Multicenter, prospective, randomized studies.Evaluation of the sensitivity to different chemotherapy regimens in platinum-partial sensitive recurrent ovarian cancer based on 11 gene tests of homologous recombination pathway.

Details

Lead sponsor	Hunan Cancer Hospital
Phase	Phase 3
Status	UNKNOWN
Enrolment	338
Start date	2017-08-01
Completion	2021-06

Conditions

• Ovarian Cancer

Interventions

• Doxorubicin Hydrochloride Liposome Injection+carboplatin
• paclitaxel +carboplatin

Primary outcomes

• PFS（Progression-Free-Survival) — up to 24months
  From the date of randomization to the time of tumor progression

Countries

China